Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells

被引：0
|
作者：
Brentjens, Renier J. [1 ]
Hollyman, Daniel [1 ]
Park, Jae [1 ]
Santos, Elmer [1 ]
Yeh, Raymond [1 ]
Stefanski, Jolanta [1 ]
Taylor, Clare [1 ]
Weiss, Mark A. [1 ]
Filippa, Daniel [1 ]
Riviere, Isabelle [1 ]
Sadelain, Michel W. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1335 / 1335
页数：1
相关论文
共 50 条
  • [21] A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies
    Park, Jae H.
    Riviere, Isabelle
    Sikder, Devanjan S.
    Bermudez, Vladimir P.
    Senechal, Brigitte
    Wang, Xiuyan
    Auchincloss, Thomas H.
    Diamonte, Claudia
    Halton, Elizabeth
    Palomba, M. Lia
    Brentjens, Renier J.
    Sadelain, Michel
    BLOOD, 2020, 136
  • [22] CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients
    Mueller, Fabian
    Voelkl, Simon
    Mougiakakos, Dimitrios
    Boeltz, Sebastian
    Aigner, Michael
    Gary, Regina
    Kretschmann, Sascha
    Kharboutli, Soraya
    Kleyer, Arnd
    Simon, David
    Roesler, Wolf
    Habenicht, Katharina M.
    Winkler, Thomas H.
    Kroenke, Gerhard
    Schett, Georg
    Mackensen, Andreas
    BLOOD, 2022, 140 : 4562 - 4563
  • [23] A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Park, Jae H.
    Palomba, Maria Lia
    Devlin, Sean M.
    Valtis, Yannis K.
    Sikder, Devanjan S.
    Senechal, Brigitte
    Wang, Xiuyan
    Cathcart, Elizabeth
    Liotta, Kelly
    Yu, Alina
    Stocker, Kelsey
    Zhang, Honglei
    Schoder, Heiko
    Leithner, Doris
    Li, Jia
    Sellner, Leopold
    Mansilla-Soto, Jorge
    Riviere, Isabelle
    Sadelain, Michel
    BLOOD, 2023, 142
  • [24] A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Park, Jae H.
    Palomba, M. Lia
    Riviere, Isabelle
    Sikder, Devanjan S.
    Senechal, Brigitte
    Wang, Xiuyan
    Bermudez, Vladimir P.
    Cathcart, Elizabeth R.
    Liotta, Kelly
    Joseph, Jannakie
    Li, Jia
    Zhao, Yunqi
    Liu, Rachael
    Chen, Sharon
    Sellner, Leopold
    Sadelain, Michel
    BLOOD, 2022, 140
  • [25] A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
    Curioni, A.
    Britschgi, C.
    Hiltbrunner, S.
    Bankel, L.
    Gulati, P.
    Weder, W.
    Opitz, I.
    Lauk, O.
    Caviezel, C.
    Knuth, A.
    Munz, C.
    Renner, C.
    Stahel, R. A.
    Petrausch, U.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
    Adusumilli, Prasad S.
    Zauderer, Marjorie G.
    Rusch, Valerie W.
    O'Cearbhaill, Roisin E.
    Zhu, Amy
    Ngai, Daniel A.
    McGee, Erin
    Chintala, Navin K.
    Messinger, John C.
    Vincent, Alain
    Halton, Elizabeth F.
    Diamonte, Claudia
    Pineda, John
    Modi, Shanu
    Solomon, Stephen B.
    Jones, David R.
    Brentjens, Renier J.
    Riviere, Isabelle
    Sadelain, Michel
    CANCER RESEARCH, 2019, 79 (13)
  • [27] A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells
    Kochenderfer, James N.
    Dudley, Mark E.
    Stetler-Stevenson, Maryalice
    Wilson, Wyndham H.
    Janik, John E.
    Nathan, Debbie-Ann N.
    Maric, Irina
    Raffeld, Mark
    Feldman, Steven A.
    Morgan, Richard A.
    Rosenberg, Steven A.
    BLOOD, 2010, 116 (21) : 1179 - 1180
  • [28] Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART 19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses
    Grupp, Stephan A.
    Kalos, Michael
    Barrett, David M.
    Teachey, David T.
    Levine, Bruce
    Milone, Michael
    Porter, David
    June, Carl H.
    CANCER RESEARCH, 2013, 73 (08)
  • [29] A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia.
    Park, Jae Hong
    Riviere, Isabelle
    Wang, Xiuyan
    Senechal, Brigitte
    Bernal, Yvette
    Halton, Elizabeth
    Diamonte, Claudia
    Wang, Yongzeng
    Brentjens, Renier J.
    Sadelain, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] A Phase I Clinical Trial of Malignant Pleural Disease Treated with Regionally Delivered Autologous Mesothelin-Targeted CAR T Cells: Safety and Efficacy - A Preliminary Report
    Adusumilli, Prasad S.
    Zauderer, Marjorie
    Rusch, Valerie
    O'Cearbhaill, Roisin
    Ngai, Daniel
    Chintala, Nain
    Halton, Elizabeth
    Diamonte, Claudia
    Modi, Shanu
    Solomon, Stephen
    Brentjens, Renier
    Riviere, Isabelle
    Sadelain, Michel
    MOLECULAR THERAPY, 2018, 26 (05) : 158 - 159
12345